205 related articles for article (PubMed ID: 15781649)
1. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
2. Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells.
Haag C; Stadel D; Zhou S; Bachem MG; Möller P; Debatin KM; Fulda S
Gut; 2011 Feb; 60(2):225-37. PubMed ID: 20876774
[TBL] [Abstract][Full Text] [Related]
3. Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin.
Hwang JS; Lee HC; Oh SC; Lee DH; Kwon KH
Tumour Biol; 2015 Nov; 36(11):8819-29. PubMed ID: 26063410
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.
Baranski Z; de Jong Y; Ilkova T; Peterse EF; Cleton-Jansen AM; van de Water B; Hogendoorn PC; Bovée JV; Danen EH
Oncotarget; 2015 Nov; 6(34):36113-25. PubMed ID: 26416351
[TBL] [Abstract][Full Text] [Related]
5. Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.
Kunze D; Erdmann K; Froehner M; Wirth MP; Fuessel S
Int J Mol Sci; 2013 Jun; 14(6):12297-312. PubMed ID: 23749114
[TBL] [Abstract][Full Text] [Related]
6. Targeting Bcl-2-mediated cell death as a novel therapy in pancreatic cancer.
Muilenburg DJ; Coates JM; Virudachalam S; Bold RJ
J Surg Res; 2010 Oct; 163(2):276-81. PubMed ID: 20452611
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Masuda Y
J Chemother; 2023 Sep; 35(5):435-447. PubMed ID: 36134604
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin.
Cao C; Pei Y; Yu H; Qi H
J Chemother; 2024 Apr; 36(2):156-166. PubMed ID: 37309095
[TBL] [Abstract][Full Text] [Related]
9. Treatment combinations targeting apoptosis to improve immunotherapy of melanoma.
Hersey P; Zhang XD
Cancer Immunol Immunother; 2009 Nov; 58(11):1749-59. PubMed ID: 19551381
[TBL] [Abstract][Full Text] [Related]
10. IL20RB signaling enhances stemness and chemotherapy resistance in pancreatic cancer.
Li XH; Huang GZ; Xu ZL; Zhao CY; Dong XY; Cui BK; Lin XJ
J Transl Med; 2023 Dec; 21(1):911. PubMed ID: 38098005
[TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888.
Kaplan Ö
Med Oncol; 2023 Oct; 40(11):318. PubMed ID: 37794195
[TBL] [Abstract][Full Text] [Related]
12. Conformational States of the Cytoprotective Protein Bcl-xL.
Ryzhov P; Tian Y; Yao Y; Bobkov AA; Im W; Marassi FM
Biophys J; 2020 Oct; 119(7):1324-1334. PubMed ID: 32888404
[TBL] [Abstract][Full Text] [Related]
13. The molecular mechanisms of chemoresistance in cancers.
Zheng HC
Oncotarget; 2017 Aug; 8(35):59950-59964. PubMed ID: 28938696
[TBL] [Abstract][Full Text] [Related]
14. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer.
Zhang W; Fan Y; Zhang J; Shi D; Yuan J; Ashrafizadeh M; Li W; Hu M; Abd El-Aty AM; Hacimuftuoglu A; Linnebacher M; Cheng Y; Li W; Fang S; Gong P; Zhang X
Drug Resist Updat; 2023 Nov; 71():101005. PubMed ID: 37647746
[TBL] [Abstract][Full Text] [Related]
15. The role of apoptosis in the pathology of pancreatic cancer.
Samm N; Werner K; Rückert F; Saeger HD; Grützmann R; Pilarsky C
Cancers (Basel); 2010 Dec; 3(1):1-16. PubMed ID: 24212603
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis in colorectal cancer.
Stoian M; State N; Stoica V; Radulian G
J Med Life; 2014 Jun; 7(2):160-4. PubMed ID: 25408720
[TBL] [Abstract][Full Text] [Related]
17. Correction:
Gut; 2024 Apr; 73(5):e8. PubMed ID: 38580381
[No Abstract] [Full Text] [Related]
18. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
[TBL] [Abstract][Full Text] [Related]
19. A redox-responsive self-assembling COA-4-arm PEG prodrug nanosystem for dual drug delivery suppresses cancer metastasis and drug resistance by downregulating hsp90 expression.
Zhou Y; Miao Y; Huang Q; Shi W; Xie J; Lin J; Huang P; Yue C; Qin Y; Yu X; Wang H; Qin L; Chen J
Acta Pharm Sin B; 2023 Jul; 13(7):3153-3167. PubMed ID: 37521875
[TBL] [Abstract][Full Text] [Related]
20. Ligand-based active targeting strategies for cancer theranostics.
Bandyopadhyay A; Das T; Nandy S; Sahib S; Preetam S; Gopalakrishnan AV; Dey A
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3417-3441. PubMed ID: 37466702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
